Skip to main content
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Atara Biotherapeutics, Inc. - Common Stock (NQ:ATRA)

12.17 +0.12 (+1.00%)
Streaming Delayed Price Updated: 12:47 PM EDT, Sep 22, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Atara Biotherapeutics, Inc. - Common Stock

< Previous 1 2 3 4 5 6 7 8 9 10 11 Next >
Crude Oil Rises Over 1%; Tapestry Posts Upbeat Earnings
U.S. stocks traded slightly higher midway through trading, with the Nasdaq Composite gaining around 50 points on Thursday. The Dow traded up 0.01% to 34,114.64 while the NASDAQ rose 0.35% to 13,697.53.... 
Via Benzinga
Topics Stocks
US Stocks Mostly Flat; Jobless Claims Decline In Latest Week
U.S. stocks traded mostly flat this morning, following the release of jobless claims data. Following the market opening Thursday, the Dow traded down 0.02% to 34,105.13 while the NASDAQ rose 0.01% to... 
Via Benzinga
Topics Stocks
Why AppLovin Shares Are Trading Higher By Over 15%; Here Are 20 Stocks Moving Premarket
Gainers Intelligent Bio Solutions Inc. (NASDAQ: INBS) shares surged 111.9% to $0.4810 in pre-market trading after reporting first-quarter results. 
Via Benzinga
Astra Space (ASTR) Stock Spikes 82% on Take-Private Proposal
Astra Space stock is taking off on Thursday as investors react to a take-private offer for ASTR shares from the company's founders. 
Via InvestorPlace
Atara Biotherapeutics's Earnings Outlook
 
Via Benzinga
Atara Biotherapeutics Earnings Perspective: Return On Capital Employed
 
Via Benzinga
Why Is Assertio (ASRT) Stock Down 39% Today?
Assertio stock is dropping on Thursday as investors in ASRT react to the company's poor earnings results for the third quarter of 2023. 
Via InvestorPlace
Why Is Atara Biotherapeutics (ATRA) Stock Down 50% Today?
Atara Biotherapeutics stock is falling on Thursday as investors in ATRA react to the company's latest Phase 2 clinical trial data. 
Via InvestorPlace
Why Atara Biotherapeutics Shares Are Plummeting Today
Atara Biotherapeutics, Inc. (NASDAQ: ATRA) shares are trading lower after the company said that primary analysis data from its Phase 2 EMBOLD study of ATA188 in non-active progressive multiple... 
Via Benzinga
12 Health Care Stocks Moving In Thursday's Pre-Market Session
 
Via Benzinga
Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Thursday
It's time to start the day with a breakdown of the biggest pre-market stock movers worth keeping tabs on for Thursday morning! 
Via InvestorPlace
Atara Biotherapeutics Announces Primary Analysis Data from Phase 2 EMBOLD Clinical Trial of ATA188 in Non-Active Progressive Multiple Sclerosis
From Atara Biotherapeutics, Inc.
Via Business Wire
Atara Biotherapeutics Announces Expanded Global Tab-cel® Partnership with Pierre Fabre Laboratories and Third Quarter 2023 Financial Results
From Atara Biotherapeutics, Inc.
Via Business Wire
10 Health Care Stocks Whale Activity In Today's Session
 
Via Benzinga
Atara Biotherapeutics, Inc. Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
From Atara Biotherapeutics, Inc.
Via Business Wire
Why Gorilla Technology Group Shares Are Trading Lower By 25%? Here Are Other Stocks Moving In Wednesday's Mid-Day Session
Gainers MSP Recovery, Inc. (NASDAQ: LIFW) shares jumped 104.5% to $0.1916. 
Via Benzinga
Atara Biotherapeutics Announces Plans to Submit Tab-cel® BLA in Q2 2024 Following FDA Agreement on Comparability
From Atara Biotherapeutics, Inc.
Via Business Wire
Atara Biotherapeutics, Inc. Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
From Atara Biotherapeutics, Inc.
Via Business Wire
Atara Biotherapeutics to Participate in Cell Therapies in Autoimmune Panel Discussion at the Citi 18th Annual BioPharma Conference
From Atara Biotherapeutics, Inc.
Via Business Wire
12 Health Care Stocks Moving In Thursday's Intraday Session
 
Via Benzinga
12 Health Care Stocks Moving In Tuesday's After-Market Session
 
Via Benzinga
Atara Biotherapeutics Announces Second Quarter 2023 Financial Results and Operational Progress
From Atara Biotherapeutics, Inc.
Via Business Wire
Atara Biotherapeutics, Inc. Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
From Atara Biotherapeutics, Inc.
Via Business Wire
Atara Biotherapeutics to Announce Second Quarter 2023 Financial Results on Tuesday, August 8, 2023
From Atara Biotherapeutics, Inc.
Via Business Wire
Atara Biotherapeutics to Participate in the Canaccord Genuity 43rd Annual Growth Conference
From Atara Biotherapeutics, Inc.
Via Business Wire
3 Doomed Biotech Stocks Destined for Disaster
Doomed biotech stocks are a major part of the natural cycle within the sector that results in a lot of failures. 
Via InvestorPlace
Atara Biotherapeutics, Inc. Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
From Atara Biotherapeutics, Inc.
Via Business Wire
Atara Biotherapeutics to Participate in the Goldman Sachs 44th Annual Global Healthcare Conference
From Atara Biotherapeutics, Inc.
Via Business Wire
Atara Biotherapeutics Presents Updated Tab-cel® Clinical Effectiveness Data at ASCO 2023
From Atara Biotherapeutics, Inc.
Via Business Wire
Atara Biotherapeutics, Inc. Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
From Atara Biotherapeutics, Inc.
Via Business Wire
< Previous 1 2 3 4 5 6 7 8 9 10 11 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms Of Service.